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 Yin and yang of interleukin-17 in host immunity to infection
[version 1; referees: 2 approved]
Shibali Das, Shabaana Khader
Department of Molecular Microbiology, Washington University in St. Louis, St Louis, MO, USA
Abstract
The interleukin-17 (IL-17) family cytokines, such as IL-17A and IL-17F, play
important protective roles in host immune response to a variety of infections
such as bacterial, fungal, parasitic, and viral. The IL-17R signaling and
downstream pathways mediate induction of proinflammatory molecules which
participate in control of these pathogens. However, the production of IL-17 can
also mediate pathology and inflammation associated with infections. In this
review, we will discuss the yin-and-yang roles of IL-17 in host immunity to
pathogens.
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Introduction
The interleukin-17 (IL-17) cytokine family is composed of six 
defined members, including IL-17A through IL-17F1. Among 
the IL-17 family members, IL-17A and IL-17F have the best- 
characterized proinflammatory activity. Although the genes 
encoding IL-17A and IL-17F are both located on chromosome 
1 and 6 (respectively), in mice and humans2, their functions 
can be similar or distinct, depending on the type of infection3. 
Although other members of the IL-17 family such as IL-17B, IL-
17C, and IL-17D can also induce the production of proinflamma-
tory cytokines and chemokines4, their functions are not as well 
characterized and will be only briefly summarized. The IL-17 
cytokine family employs various cytokine receptors (IL-17RA, 
IL-17RB, IL-17RC, IL-17RD, and IL-17RE) on target cells to 
mediate their biological functions5. IL-17R is a heteromeric 
receptor comprising IL-17RA and IL-17RC and mediates signal-
ing of IL-17A and IL-17F. In contrast, partnering of IL-17RA 
with IL-17RB is thought to mediate IL-17E signaling whereas 
IL-17RA partnering with IL-17RE mediates IL-17C signaling5. 
IL-17Rs are ubiquitously expressed in various cell types ranging 
from leukocytes to fibroblasts, epithelial cells, mesothelial cells, 
endothelial cells, and keratinocytes6,7. IL-17A or IL-17F mediates 
their biological function through the IL-17R via the activation of 
nuclear factor-kappa B (NF-κB) and mitogen-activated protein 
kinase (MAPK), leading to the production of proinflammatory 
cytokines and chemokines8–11. Tumor necrosis factor receptor- 
associated factor 6 (TRAF-6) plays an indispensable role in 
IL-17R signaling as IL-17 stimulation fails to activate IL-17R 
signaling in TRAF-6-deficient mouse embryonic fibroblasts12,13. 
In addition, NF-κB activator 1 (Act1) is important for IL-17R 
signaling, where it acts as an adapter molecule for the recruitment 
of TRAF-6 with IL-17R14,15. In this review, we will use IL-17 to 
refer to IL-17A.
Upon exposure to pathogen or pathogen-associated molecular 
patterns (PAMPs), dendritic cells, monocytes, and macrophages 
induce cytokines such as IL-23, IL-1β, IL-6, and transforming 
growth factor-beta (TGF-β), which initiate the differentiation and 
polarization of naïve CD4+ T cells toward the T helper cell type 
17 (Th17) subsets16. Low levels of TGF-β support induction of 
the transcription factor RAR-related orphan receptor gamma 
(RORγ) and differentiation toward a Th17 subset, while high 
levels of TGF-β along with defined cytokines such as IL-2 
mediate transition to regulatory T cells (Tregs) through 
the activation of the transcription factor, fork head box P3 
(Foxp3)17–19. Th17 cells are considered a primary source of IL-17 
and co-produce other cytokines, including IL-22, IL-21, tumor 
necrosis factor-alpha (TNF-α), and granulocyte macrophage-
colony-stimulating factor (GM-CSF)20,21. However, depending on 
the cytokine milieu, Th17 cells can exhibit substantial plasticity 
in cytokine production22. Th17 cells can also co-express GATA 
binding protein 3 (GATA-3) or T-box transcription factor (T-bet), 
allowing them to progress into either IL-4-expressing or interferon-
gamma (IFN-γ)-expressing Th17 subsets23. Thus, it is likely that 
during infection in vivo, Th17 cells exhibit substantial plasticity 
and can co-express Th17 cytokines along with other Th1, Th2, and 
Treg-associated cytokines. Additionally, in response to early IL-23 
and IL-1β production by myeloid cells, innate cells such as γδ 
T cells24 and group 3 innate lymphoid cells (iLC3)25,26 can produce 
IL-17 and mediate early immune responses. Other immune cells 
such as neutrophils27–29, invariant natural killer T (iNKT)30 cells, 
innate Th17 cells (iTh17)31, and natural killer (NK)32 cells can also 
produce IL-17 through stimulation of TGF-β, IL-1β, IL-6, IL-23, 
or alpha-galactoceramide (α-galcer)33. A primary mechanism by 
which IL-17 mediates protection against pathogens (such as 
Klebsiella, Candida, and Chlamydia) is through the induction of 
chemokines and cytokines and downstream recruitment of neu-
trophils34,35. IL-17 can act alone or in synergy with other cytokines 
such as TNF-α and IL-22 to mediate induction of neutrophil- 
recruiting chemokines such as granulocyte-colony-stimulating 
factor (G-CSF) and C-X-C motif chemokine ligand 1 (CXCL1) 
and regulate neutrophil-mediated destruction of pathogens36. 
In addition, IL-17 alone or synergistically with IL-22 or 1,25- 
dihydroxyvitamin D3 induces the expression of anti-microbial 
proteins such as Lipocalin-237, β-defensin38, S100A7 (psoriasin), 
S100A8/9 (calprotectin), and cathelicidin (LL37), resulting in 
pathogen control11, likely through direct anti-microbial actions. 
Our recent knowledge on the role of IL-17 in immunity to various 
pathogens, including extracellular39,40 or intracellular41–43 bacteria, 
fungi9,44, viruses45, and parasites46,47, has emerged within the past 
decade. In this short review, we will summarize the recent progress 
in the field of IL-17-mediated immune responses against various 
infections.
Role of IL-17 in immunity to extracellular bacterial 
infection
The role of IL-17 in host defense against extracellular bacteria is 
thought to be primarily through the induction of anti-microbial 
molecules and mediation of neutrophil recruitment at the site of 
infection guided by chemokine gradients. Early studies with IL-
17R-deficient mice demonstrated a critical role for IL-17 in the 
clearance of the extracellular pulmonary pathogen Klebsiella 
pneumoniae infection. IL-17R-deficient mice upon infection with 
K. pneumoniae produced lower levels of the neutrophil-driving 
cytokine G-CSF and neutrophil-recruiting chemokine, macrophage 
inflammatory protein-2 (MIP-2). These changes in cytokines and 
chemokines in IL-17R-deficient mice resulted in decreased neu-
trophil infiltration into the lung and subsequently higher bacterial 
burden along with increased mortality48. Additionally, IL-17R-defi-
cient mice are more susceptible to a variety of mucosal extracel-
lular pathogens, including the gut-specific pathogen Citrobacter 
rodentium49, skin pathogen Staphylococcus aureus50, and pulmo-
nary pathogen Bordetella pertussis51. Moreover, neutralization 
of IL-17 resulted in the suppression of anti-microbial peptide 
β-defensin production, which killed invading S. aureus at mucosal 
surfaces52. These studies provide the consensus that upon infection 
with extracellular pathogens, γδ T cells53, iLC354, and iNKT55 cells 
are important early producers of IL-17 which are associated with 
innate immunity following extracellular bacterial infections. In 
addition, Th17 cells are involved in the IL-17-mediated responses 
associated with adaptive immune responses56,57. Therefore, these 
studies suggest that induction of IL-17 and synchronized produc-
tion of anti-microbial molecules and neutrophil recruitment help 
the resolution of extracellular infection. During extracellular patho-
genesis, the major IL-17 responsive cell population is thought to 
be mucosal epithelial cells58,59. However, other studies suggest 
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that macrophage or dendritic cells (or both) also express IL-17R 
and respond to IL-17 and downstream protective responses4,54. 
Recently, it was reported that innate immune defense against a 
highly antibiotic-resistant strain of K. pneumoniae depends on 
crosstalk between inflammatory monocytes and innate lymphocytes 
which is mediated by TNF-α and IL-1754. IL-17-producing 
resident epidermal γδ T cells are essential for protecting the host 
against a subsequent staphylococcal infection60. IL-17-dependent  
neutrophil-mediated protection is also observed during sponta-
neous S. aureus infection61,62 and K. pneumoniae infection63–65. 
Although in most studies IL-17 plays a protective role during 
extracellular bacterial infections, in some cases IL-17 can also 
mediate pathology associated with the infection. For example, the 
periodontal extracellular bacteria Porphyromonas gingivalis can 
directly promote autoimmune arthritis by the induction of Toll- 
like receptor 2 (TLR2)/IL-1Rα-driven IL-17 response in DBA/1J 
mice66. Furthermore, increased frequency of IL-17+ cells was 
observed in gingival tissue of patients with periodontitis67, likely 
produced by human CD4+ T cells68. Similarly, B. pertussis infec-
tion can bias the host immune response toward IL-17 production, 
which may be associated with cough pathology in pertussis infec-
tion56,69. Additionally, IL-17 is associated with the neutrophilia 
and airway inflammation during Haemophilus influenza infection 
in mice undergoing allergic airway disease70. Thus, IL-17 has an 
important role in protective immunity to extracellular pathogens 
through release of anti-microbial proteins from cell types such 
as epithelial cells and neutrophils (and monocytes). On the other 
hand, IL-17 induced in response to infection may mediate excessive 
inflammation and pathology.
Role of IL-17 in intracellular bacterial infection
Although infection by intracellular bacteria is predominantly 
cleared by Th1 immune responses, recent studies have described 
an emerging role for IL-17 in protection against intracellular patho-
gens such as Listeria monocytogenes71, Mycoplasma pneumonia72, 
Legionella pneumophila73,74, Salmonella typhimurium75, Chlamy-
dia muridarum76, Francisella tularensis77, and Mycobacterium 
tuberculosis78. Following infection with intracellular pathogens, 
like infection with extracellular pathogens, both innate cells 
such as iLC-364 and γδ T cells79 and adaptive cells such as Th17 
cells80 are the primary producers of IL-17. But during intracellu-
lar infection, unlike extracellular infection, macrophages or mye-
loid cells have been shown to be major responder cells to IL-17. 
In response to IL-17 stimulation, macrophages and myeloid cells 
secrete higher amounts of anti-microbial cytokines such as TNF-α, 
IFN-γ, or IL-12 and contribute to host immune response against 
infections such as F. tularensis77. Although γδ T cell-derived IL-
17 has played a more prominent role in L. monocytogenes41, 
M. tuberculosis81, F. tularensis82, and Mycobacterium bovis 
Bacillus Calmette-Guérin83 infections, Th17 cells as well as CD8+ 
cells are also involved in the antigen-specific production of IL-17 at 
the site of infection84. In addition, IL-17-deficient mice experience 
higher bacterial burden associated with disorganized granuloma 
formation (reduced monocyte, granulocyte, and T cell recruitment 
within the granuloma) during infections with intracellular patho-
gens such as F. tularensis77, S. typhimurium85, or M. tuberculosis86. 
In some infection models, including C. muridarum, IL-17 
complemented the protective role imparted by the IL-12/IFN-γ 
axis through the involvement of myeloid differentiation factor 88 
(MyD88) signaling where MyD88-deficient infected mice showed 
reduced IL-17 responses along with reduced neutrophil infiltration, 
which is important for early control of disease pathogenesis87,88. 
However, excess IL-17 production is detrimental for the host, as 
IL-10-deficient mice exhibit increased mortality after pulmonary 
F. tularensis infection due to excessive inflammation induced 
by IL-1789, which suggests that IL-17 is tightly regulated by 
IL-10. However, other evidence suggests that the contribution of 
IL-17 may serve a more compensatory function under unfavora-
ble conditions such as in the absence of type I and II interferon 
signaling, where a low-magnitude IL-17 response to L. monocy-
togenes or M. tuberculosis infection is evident87,90. On the contrary, 
early studies suggest that IL-17-mediated immunity is dispen-
sable against M. tuberculosis infection as evident by the results 
obtained from either anti-IL-17 treated or IL-17R-deficient mice 
which were not more susceptible against infection with less 
virulent lab-adapted M. tuberculosis strains as compared with 
wild-type mice91,92. However, the involvement of IL-17 in 
mucosal vaccine-driven protection in murine models of tuber-
culosis seems to be crucial, as suggested by Gopal et al.93. 
IL-17-mediated induction of CXCL-9-11 is responsible for the 
recruitment of protective antigen-specific T cells as well as induc-
tion of CXCL-13 to localize C-X-C motif chemokine receptor 5 
(CXCR5)-positive cytokine-producing T cells within lung granu-
lomas of M. tuberculosis-infected mice94. Interestingly, IL-17 
responses were involved in protection against a hyper-virulent 
clinical isolate M. tuberculosis HN878 strain, as IL-17-deficient 
mice infected with M. tuberculosis HN878 had significantly 
higher bacterial burden along with reduced chemokine expression 
and less organized granuloma formation95. However, there are 
some contradictory views regarding the role of IL-17 in the con-
text of human tuberculosis. Some studies support the protective 
role of IL-17 during human tuberculosis as IL-17 helps in the gen-
eration of proinflammatory cytokines such as IL-12 and IFN-γ and 
restricts pathogenesis within the host96. In contrast, other reports 
identified that IL-17 had a negative correlation with tuberculosis 
treatment and disease outcome97. In addition, IL-17-producing 
T cells are reported to play an immunopathological role in 
patients with multidrug-resistant M. tuberculosis by promot-
ing severe tissue damage, which may be associated with low 
effectiveness of the second-line drugs employed during 
treatment97. Moreover, IL-23-dependent IL-17 production is 
associated with neutrophil accumulation and inflammation dur-
ing a chronic re-stimulation model of tuberculosis98. Indeed, 
exacerbated production of IL-17 appears to drive pathology by 
inducing S100A8/A9 proteins that recruit neutrophils into the 
lung99 and cause excessive inflammation in mice during tuber-
culosis. Therefore, at least in the context of tuberculosis, the 
M. tuberculosis strain to some extent specifically dictates the 
protective role of IL-17. Therefore, during intracellular patho-
gen infections, although IL-17 is mostly associated with host 
protection through regulation of chemokine and cytokine balance 
and infiltration of different immune cells to the site of infection, 
IL-17 activity should be tightly regulated in order to maintain the 
fine balance between protection and pathology induced by IL-17.
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Role of IL-17 during sepsis
Although sepsis is a syndrome rather than a disease itself, the role 
for IL-17 in experimental murine sepsis models and human sepsis 
has been studied. In a colitis model, both IL-17-deficient mice and 
mice treated with IL-17 neutralizing antibody resulted in signifi-
cant improvement in survival which was associated with reduced 
disease pathology and decreased bacteremia100,101. In line with this 
observation, IL-17 also drives sepsis-associated acute kidney injury 
by increasing the levels of proinflammatory cytokines and induc-
ing neutrophil accumulation and tubular epithelial cell apoptosis102 
in mouse models. More recently, targeting IL-17 has been shown 
to attenuate IL-18-dependent disease severity in a neonatal sepsis 
mouse model103. In vitro studies with the peripheral blood mononu-
clear cells (PBMCs) from healthy donors and patients undergoing 
severe sepsis showed increased Th17 cells in patients with sepsis 
when compared with healthy donors. Additionally, IL-17 neutrali-
zation increased IL-10 production in PBMCs, suggesting a role for 
IL-10 in modulating immune responses during sepsis104. Thus, IL-
17 has a pathological role in sepsis, and targeting IL-17 may serve 
to resolve sepsis and sepsis-induced pathogenesis.
Role of IL-17 in parasitic infection
Although IL-17 has been considered an important player in 
the mediation of host protection against extracellular and some 
intracellular pathogens, the role of IL-17 in host defense against 
intracellular protozoan parasites remains less well studied. Infec-
tion studies demonstrate that Th17 cells mediate host defense 
against Trypanosoma cruzi105, Toxoplasma gondii106, Leishmania 
braziliensis107, and Echinococcus granulosus108 infections. NK 
cells are a major source of IL-17 during toxoplasmosis32. In addi-
tion, CD4+ and CD8+ cells express IL-17 in human toxoplasmo-
sis and impact human pregnancy by controlling parasite invasion 
and replication which often cause fetal malfunction or abortion109. 
Increased IL-17 levels were detected in the PBMCs and tissue from 
leishmaniasis-infected patients and associated with enhanced neu-
trophil and macrophage-mediated destruction of the parasite110. 
Furthermore, IL-17R-deficient mice were associated with reduced 
production of the chemokine MIP-2 along with the suboptimal lev-
els of neutrophil recruitment and higher parasitic load as compared 
with wild-type counterparts111. Additionally, during echinococ-
cosis, IL-17 plays a crucial immune protective role by regulating 
the Tregs which are associated with tolerance during infection112. 
In contrast, in human cutaneous leishmaniasis113–115 and Eimeria 
tenella infection in chickens116, IL-17 contributed to the pathology 
through excessive inflammation and subsequent tissue damage. A 
recent report suggests that Leishmania guyanensis is associated 
with a cytoplasmic virus which enhances parasite virulence and is 
linked to increased IL-17 levels induced following L. guyanensis 
infection115. Neutralization of IL-17 was effective in reducing dis-
ease severity in a mouse model of cutaneous leishmaniasis, sug-
gesting that IL-17 may have a strain-specific immunological role 
during leishmaniasis infection115. Despite having a protective role 
against T. gondii infection, IL-17 had a deleterious effect that is 
evident where neutralization of IL-17 had a partial protective role 
against the fatal disease117, through co-production of IL-10 and 
IFN-γ which regulated the exacerbated inflammation induced by 
IL-17. Taken together, these reports argue with previous reports 
and present new evidence in favor of the pathological role of IL-17 
during parasitic infections. Therefore, during parasitic infection, 
the role of IL-17, whether protective or pathologic, has yet to be 
firmly established.
Role of IL-17 in fungal infection
IL-17 plays an immunologically important host protective 
role against fungal pathogens such as Candida albicans118, 
Cryptococcus neoformans119, Pneumocystis carinii120, and 
Aspergillus fumigatus121 in both humans and mice. Similar to the 
mechanisms seen in the intracellular and extracellular bacterial 
infections, fungal pathogens elicit IL-17 protective effects through 
the release of proinflammatory cytokines, chemokines, and anti-
microbial peptides. During infection, IL-17 is expressed by various 
cell types, including oral resident γδ T cells122, iLC3123, and natural 
Th17 cells122. Moreover, the IL-17 cytokine family contributes in 
the development of NK cells which promote anti-fungal immu-
nity by secreting GM-CSF, necessary for the fungicidal activity of 
neutrophils124,125. Recent advances in the field of oral candidiasis 
depict oral epithelial cells (OECs) as the major responder cells 
to IL-17 signaling126. These OECs produce β-defensin 3 through 
IL-17R signaling which is necessary for protection against oral 
candidiasis through both a neutrophil-dependent and -independent 
manner118. Caspase recruitment domain family member 9 
(CARD-9) signaling is associated with the production of IL-17 
during fungal infections127. Accordingly, humans with CARD-9128 
or IL-17R deficiency have increased mucocandidiasis129 and are 
more vulnerable during systemic candidiasis124, and decreased 
IL-17 production is associated with increased susceptibility to 
fungal pathogens130. These studies suggest that fungal pathogens 
are dependent on IL-17-mediated recruitment of inflammatory 
cells for fungal control. In contrast, IL-17C subset is associated 
with lethal inflammation during candidiasis through induction of 
proinflammatory cytokines in renal epithelial cells131. Moreover, 
the IL-23/IL-17 pathway promotes inflammation and susceptibil-
ity to fungal infectious disease models such as C. albicans and 
A. fumigatus through excessive inflammation, which impairs anti-
fungal resistance against those infections132–134. Therefore, critical 
observation on the particular role played by the IL-17 cytokine 
family is necessary before considering IL-17 signaling as a 
potential drug target.
Role of IL-17 in viral infection
Recent studies have addressed whether IL-17 is protective or 
pathologic in response to viral infections such as influenza (H1N1, 
H5N1), vaccinia virus, Epstein-Barr virus (EBV), herpes simplex 
virus (HSV), respiratory syncytial virus (RSV), human immuno-
deficiency virus (HIV), and hepatitis (B and C). Although several 
studies have suggested a protective role imparted by IL-17 signal-
ing in host immunity during influenza infection, other studies have 
suggested a more pathological role instead. For example, it has 
been observed that depletion of IL-17 resulted in a more severe 
disease outcome in a mouse model of influenza, which was associ-
ated with increased weight loss as well as reduced survival135,136. 
Furthermore, adoptive transfer of Th17 polarized antigen-specific 
effector cells has been shown to be protective in mice challenged 
with a lethal dose of influenza, thus suggesting a protective role 
for IL-17 that is independent of IFN-γ137. In contrast, IL-17R-defi-
cient mice have also been shown to have reduced neutrophil influx 
and decreased inflammation, suggesting a pathological role for 
IL-17 during influenza challenge138,139. The genetic background of 
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mice used and the influenza dose used were different between the 
studies, suggesting a protective or pathological role for IL-17 in 
influenza. Therefore, these studies suggest that the genetic back-
ground and infectious dose may act as a determining factor regard-
ing  the protective or pathologic role of  IL-17 during influenza 
infection. In contrast, IL-17 is associated with the pathology in 
2009 pandemic influenza A (H1N1)-induced acute lung injury140. 
Additionally, IL-17 levels are associated with the exacerbated 
disease pathology induced following viral infections such as 
hepatitis141,142, vaccinia virus143,144, RSV145–147, HSV148,149, and 
EBV150,151. During viral infections (such as hepatitis), IL-17 can 
either potentiate early neutrophil infiltration at the site of infection152 
or inhibit NK cell-mediated host immune response (for exam-
ple, vaccinia virus infection)153. Neutralization of IL-17 not only 
reduced the disease severity but also reduced the viral load in 
the host and improved survival of the host during HSV72,148 and 
Dengue virus154 infections. Despite having a pathological role 
against most viral infections, IL-17 was suggested in several 
reports to have a protective role during HIV infection. Along with 
the Th17 cells, a subset of CD8+ cells which produce IL-17, also 
known as TC17, are important in the context of viral infection, 
although the detailed role of TC17 has yet to be delineated155,156. 
Moreover, Treg/Th17 ratios dictate the outcome of infection as 
well as effectiveness of anti-retroviral treatment157,158. Therefore, 
the balance between the Treg and Th17/Tc17 is suggested to 
be more important than that of the expression of IL-17 alone159. 
However, some recent data also suggest that during HIV infection 
IL-17 levels have a negative correlation with HIV plasma viral 
load160. Therefore, these data together suggest that IL-17 may 
be contributing to the inflammatory injury in response to viral 
infection, but the recruitment of inflammatory cells such as 
neutrophils or lymphocytes may be required for protection. We 
propose that the full array of IL-17 responses during various viral 
infections has yet to be fully delineated.
Anti-IL-17 therapies and impact on host immunity to 
infections
Exacerbated IL-17 production is linked to excessive inflammation 
-associated complications such as autoimmunity, chronic 
obstructive pulmonary disease (COPD), and contact dermatitis. 
Moreover, P. gingivalis infection predisposes the patient to the 
potential risk of acquiring autoimmune disorders, specifically 
rheumatoid arthritis (RA)161,162 through excessive inflammation 
(induced by IL-17) or generation of autoantibodies. As a result, 
diseases such as psoriasis163, RA164, and contact dermatitis165 are 
emerging as particularly strong IL-17-driven disorders. Similarly, 
excessive IL-17 leads to the upregulation of neutrophil-attracting 
chemokines and subsequent neutrophil infiltration and inflam-
mation during COPD166,167. A number of biologic drugs targeting 
IL-17A/F and IL-17RA are being used or evaluated as treatment 
options against several diseases, such as COPD168, psoriasis, and 
RA, with impressive efficacy169,170. However, IL-17 is strongly asso-
ciated with the protection against Mtb clinical isolates and fungal 
infections. IL-17 and IL-17RA single-nucleotide polymorphisms 
enhance the risk of fungal diseases such as candidiasis171 and 
bacterial disease such as pulmonary tuberculosis in certain 
cohorts172,173. Moreover, deficiency in CARD-9174 or gain of 
function of signal transducer and activator of transcription 1 
(STAT-1)175 impairs IL-17 signaling and these mutations are asso-
ciated with the chronic candidiasis. Therefore, we suggest that 
anti-IL-17 treatments may have a detrimental effect on the overall 
immunity of those individuals as they may become immunocom-
promised, resulting in predisposition toward the risk of acquiring 
several infections (including Candida176 and Mycobacterium177).
Conclusions
The importance of IL-17 in different infectious models is now 
well established. Although there are several infections where the 
role of IL-17 is not clear, IL-17 plays distinct yin-and-yang roles 
in a majority of the cases. IL-17 plays a protective role against 
the infection, and excess IL-17 promotes pathology and tissue 
destruction. The overall global role for the involvement of IL-17 
in infection models is summarized in Figure 1 and Table 1. Upon 
Figure 1. Yin-and-yang roles of IL-17 during infections. As the 
host immune system encounters a pathogen, host immune cells 
respond by releasing an array of cytokines such as IL-23, IL-6, and 
IL-1β. (A) These cytokines elicit IL-17 production from both innate 
cells (iLC3, NK, iNKT, iTH17, and γδ T) and adaptive cells (Th17 and 
Tc17). (B) This IL-17 then acts on responder cells, which express 
IL-17Rs on the cell surface, such as epithelial cells or myeloid 
cells. (C) Through IL-17R signaling, these responder cells produce 
chemokines which help recruit neutrophils to the site of infection. 
(D) These recruited neutrophils destroy the pathogen (mostly 
extracellular) through the production of cytokines, chemokines, and 
anti-microbial peptides. (E) Similarly, myeloid cells are also able to 
restrict pathogen establishment through activation and recruitment 
of Th1 cells. These Th1 cells secrete proinflammatory cytokines, 
chemokines, and anti-microbial peptides to restrict pathogenesis. 
On the other hand, excessive inflammation at the site of infection 
may lead to exacerbated disease pathology. IL, interleukin; IL-17R, 
interleukin 17 receptor; iLC3, group 3 innate lymphoid cell; iNKT, 
invariant natural killer T; iTH17, innate T helper cell type 17 cell; NK, 
natural killer; Th, T helper cell type.
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Table 1. Description of infections where protective or pathologic roles of IL-17 have been demonstrated
Protective roles of IL-17 Pathologic role of IL-17
Extracellular bacteria Klebsiella pneumoniae48, Citrobacter rodentium49, 
Staphylococcus aureus50, and Bordetella pertussis51
Bordetella pertussis56,69, 
Porphyromonas gingivalis66, 
and Haemophilus influenza70
Intracellular bacteria Listeria monocytogenes71, Mycoplasma pulmonis72, 
Legionella pneumophila73,74, Salmonella typhimurium75, 
Chlamydia muridarum76, Francisella tularensis77, and 
Mycobacterium tuberculosis78 
Mycobacterium tuberculosis96–98
Parasites Trypanosoma cruzi104, Toxoplasma gondii105, 
Leishmania braziliensis106, and Echinococcus 
granulosus107
Leishmania major112,113, 
Leishmania guyanensis114, 
Eimeria tenella115, and 
Toxoplasma gondii116
Fungus Candida albicans117, Cryptococcus neoformans118, 
Pneumocystis carinii119, and Aspergillus fumigatus120
Candida albicans130–133 and 
Aspergillus fumigatus133
Virus H5N1134–136 and HIV154,155 H1N1137–139, respiratory 
syncytial virus144–146, herpes 
simplex virus147,148, Epstein-Barr 
virus149,150, vaccinia virus142,143, 
Dengue virus153, hepatitis B and 
C virus140,141, and HIV159
HIV, human immunodeficiency virus; IL-17, interleukin-17.
exposure to pathogens (bacteria, fungus, or virus), myeloid cells 
produce factors that promote the production of IL-17 from both 
innate and adaptive cells. IL-17 then acts on primary responder 
cells (epithelial, macrophage, or myeloid cells), thereby induc-
ing the production of other anti-microbial peptides, chemokines, 
and cytokines. IL-17-induced chemokines recruit neutrophils (and 
other immune cells) to the site of infection and restrict patho-
genesis. On the other hand, this pathway can mediate excessive 
inflammation and exacerbated pathology at the infectious milieu. 
Hence, careful observation on the role of IL-17 is necessary to 
improve the overall treatment strategy against such infections. 
Therefore, it is important to critically consider the yin-and-yang 
roles of IL-17 while designing novel strategies to target specific 
pathways for control of pathogens.
Abbreviations
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colony-stimulating factor; GM-CSF, granulocyte macrophage- 
colony-stimulating factor; HIV, human immunodeficiency 
virus; HSV, herpes simplex virus; IFN-γ, interferon-gamma; IL, 
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